clinical research office
clinical research office
批准号:
8135589
负责人:
TIMOTHY M KUZEL
金额:
$47.68万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AdherenceBudgetsCancer CenterChargeChemopreventionChicagoChildClinicalClinical ProtocolsClinical ResearchClinical TrialsClinical Trials Data Monitoring CommitteesCompanionsComprehensive Cancer CenterContractsCorrelative StudyCost AnalysisCritiquesDataData CollectionDatabasesDevelopmentEastern Cooperative Oncology GroupElectronicsEligibility DeterminationEnrollmentEnsureEpidemiologyEvaluationFundingFutureGrantGuidelinesHealthcareHematologyHospitalsInformation SystemsInstitutesInstitutionInternetInterventionLaboratoriesMalignant - descriptorMalignant NeoplasmsManualsMedical OncologyMedical centerMonitorObservational StudyProceduresProcessProtocols documentationRadiation OncologyRecommendationRehabilitation therapyReportingResearchResearch Ethics CommitteesResearch PersonnelResearch ProposalsResourcesSafetySiteSpecimenStructureSupervisionSurgical OncologySystemTherapeuticTherapy Clinical TrialsTimeTrainingTraining ProgramsUniversitiesWorkanticancer researchbaseelectronic datafollow-uphuman subject protectionmeetingsmemberneuro-oncologyoncologyprotocol developmentquality assuranceresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The Clinical Research Office (CRO) of the Robert H. Lurie Comprehensive Cancer Center participates at all levels in the
activation and conduct of clinical cancer research conducted through all of the affiliate network institutions. This includes
limited assistance with protocol development, scientific and procedural review of new protocols, filing of initial submission
and continuing reviews to the institutional review board, clinical research coordination, and data collection and
management, assuring quality with outside sponsors or internal reviewers, coordinating procurement of biologic
specimens for clinical/ laboratory correlates, and coordinating supervision of appropriate trials by statisticians and the
Data Monitoring Committee. In the current reporting period (8/1/05 - 7/31/06) 50 investigators have utilized this facility,
including 45 with external funding. These investigators came from 12 departments within Northwestern University; 39 of
these investigators are Cancer Center members. Since 2001, the number of studies open to accrual during each 1-year
period ranged from 386 to 449 (389 in the current period). During this time the number of studies, of all types, that were
active and requiring follow-up information ranged from 862 to 1040 (999 in the most recent period). A total of 4804
subjects were accrued to clinical trials at Cancer Center institutions from 8/05-7/06, including 3996 subjects (83%)
enrolled at the main institution and 808 (17%) at network institutions. An additional 927 subjects were enrolled at other
affiliated sites (ECOG affiliates, sites participating in local investigator-initiated trials). At Cancer Center network sites,
there were 666 subjects enrolled to therapeutic protocols, 789 to studies involving other interventions, 1025 to
epidemiologic or other observational studies, and 2324 to companion, ancillary or correlative studies. Importantly, 4332
of the 4804 (90%) total subjects, and 382 of the 666 subjects on therapeutic trials (57%), were enrolled on institutional
trials with internal or external funding. During this grant cycle, five initiatives were undertaken: 1) continued
development and enhancement of our Internet-based paperless protocol management system and clinical trial
management system (Northwestern Oncology Trial Information System-NOTIS). Most recently this initiative has included
upgrading the system to allow for roll-out of the database to our Cancer Center affiliates; 2) development of a training
program and training manual for clinical staff; 3) development and implementation of a NCI approved Data and Safety
Monitoring Plan; 4) significant review and restructuring of the financial structure of the office, resulting in enhanced
financial reporting; and 5) a comprehensive review of the CRO's protocol initiation process, resulting in recommendations
that have decreased initial protocol approval times from 32 weeks from July-December 2004, to 19 weeks
currently. Future developments for the CRO will include expansion of the NOTIS to include electronic data
capture (from main institution electronic charting resources) for local investigator-initiated trials, and further
enhancements to CRO financial tracking mechanisms that will allow the office to more efficiently and
accurately manage all financial aspects of trials (billing, CRO recharges, financial projecting, etc...).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
clinical research office
-
批准号:8486519
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2012
-
负责人:TIMOTHY M KUZEL
-
依托单位:
clinical research office
-
批准号:7339477
-
项目类别:
-
资助金额:$41.91万
-
财政年份:2007
-
负责人:TIMOTHY M KUZEL
-
依托单位:
IN VIVO GENERATION OF ANGIOSTATIN 4.5--CLINICAL TRIAL
-
批准号:6293438
-
项目类别:
-
资助金额:$26.84万
-
财政年份:2001
-
负责人:TIMOTHY M KUZEL
-
依托单位:
IN VIVO GENERATION OF ANGIOSTATIN 4.5--CLINICAL TRIAL
-
批准号:6514900
-
项目类别:
-
资助金额:$26.84万
-
财政年份:2001
-
负责人:TIMOTHY M KUZEL
-
依托单位:
clinical research office
-
批准号:8309432
-
项目类别:
-
资助金额:$45.44万
-
财政年份:--
-
负责人:TIMOTHY M KUZEL
-
依托单位:
clinical research office
-
批准号:7920986
-
项目类别:
-
资助金额:$48.77万
-
财政年份:--
-
负责人:TIMOTHY M KUZEL
-
依托单位:
PREVENT 5-FLUORACIL INDUCED COAGULATION ACTIVATION W/SUBCUTANEOUS HEPARIN
-
批准号:3893006
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:TIMOTHY M KUZEL
-
依托单位:
clinical research office
-
批准号:7666678
-
项目类别:
-
资助金额:$48.47万
-
财政年份:--
-
负责人:TIMOTHY M KUZEL
-
依托单位:
海外基金